Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00335166 · ClinicalTrials.gov registry record · Phase 3
SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease
A Phase 3 study, sponsored by Solvay Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 330
- Enrollment target
NCT00335166 is a Phase 3 study that has completed, run by Solvay Pharmaceuticals. The registered enrollment target is 330 participants.
The verdict
NCT00335166, a Phase 3 study, has completed, sponsored by Solvay Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 330 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, double blind, parallel group study of 6 months' treatment with SLV308 as monotherapy in patients with early stage PD. An open label safety extension to this study is planned as a separate protocol for patients who are willing and eligible to participate.
Interventions
- DRUG Placebo Comparator
- DRUG pramipexole
- DRUG Pardaprunox
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2006-11 |
| Est. Completion | 2008-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00335166
The ClinicalTrials.gov registry entry for NCT00335166 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Solvay Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo Comparator is the first listed.
NCT00335166 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00335166 about?
NCT00335166 is a clinical study titled "SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease". This is a multicenter, randomized, double blind, parallel group study of 6 months' treatment with SLV308 as monotherapy in patients with early stage PD. An open label safety extension to this study is planned as a separate protocol for patients who are willing and eligible to participate.
What is the current status of trial NCT00335166?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 330 participants. The study started on 2006-11. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00335166?
The interventions under investigation include: Placebo Comparator (DRUG), pramipexole (DRUG), Pardaprunox (DRUG).
Who is sponsoring clinical trial NCT00335166?
This trial is sponsored by Solvay Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.